代表取締役

中岡 茂　(Shigeru Nakaoka, CEO)

経営／診断システム開発／診断薬開発支援／医療研究者・企業連携
　診断薬メーカーのダイナボット株式会社（現アボットジャパン株式会社）にて14年にわたり事業開発と研究開発に従事し、感染症診断薬を中心に５つの新製品開発に携わる。2003年より富士レビオ株式会社にて主席研究員として新規マーカーの臨床試験を主導。診断薬開発に関するシード探索から共同研究、製品開発、申請対応、マーケティング、販売管理までのメーカー業務全般に通じている。診断薬専門のコンサルティングファーム顧問および医療ベンチャーのシニアマーケティングディレクターを経て、当社代表取締役就任　　　　　　　　　　　　　　　　　　　　　
Management / In Vitro Diagnostics Development Support / Medical Researcher-Manufacturer Collaboration
　I have been engaged in business development and R&D for 14 years at Diagnabot Corporation (now Abbott Japan Co., Ltd.), a diagnostics manufacturer, where I was involved in the development of five new products, mainly diagnostics for infectious diseases. I have led clinical trials of novel markers as a principal researcher at Fujirebio, Inc. since 2003. I have extensive experience in all aspects of diagnostics development, from seed discovery, joint research, product development, and application handling, to marketing and sales management. After working as an advisor to a consulting firm specializing in diagnostic products and as a senior marketing director of a medical venture company, he became a representative director of our company.

取締役

中山 登 (Noboru Nakayama, CSO)

科学技術／新技術開発／創薬支援
　日本ロッシュ研究所天然物化学部機器分析グループ長、中外製薬株式会社研究本部化学部分析グループ長を務めた。リードコンパウンドスクリーニングからADMETハイスループットスクリーニング、前臨床研究など創薬研究に長年従事し、LC/MS、NMRなどの分析機器の理論と創薬における分析に深い経験と知識を有する。現在、バイオシステクノロジーズ取締役CTO、聖マリアンナ医科大学分子病態情報講座非常勤講師

Science and Technology / New Technology Development / Drug Discovery Support
　I served as head of the Instrumental Analysis Group, Natural Products Chemistry Department, Roche Research Laboratories, Japan, and as head of the Analytical Group, Chemistry Department, Research Division, Chugai Pharmaceutical Co. I have long been engaged in drug discovery research from lead compound screening to ADMET high-throughput screening and preclinical research, and has deep experience and knowledge in the theory of analytical instruments such as LC/MS and NMR and their analysis in drug discovery. Currently, Director and CTO of Biosys Technologies, Inc. and Adjunct Lecturer at St. Marianna University School of Medicine, Department of Molecular Pathophysiology and Informatics.

取締役

板東 泰彦 (Yasuhiko Bando, Managing Director)

事業開発（化学分析技術、分析機器）
　バーモント州St.Michael’s College Master of Science Administration 終了（修士）。株式会社サイプレス・インターナショナル設立（前代表取締役）、エーエムアール株式会社分析事業部設立（現取締役）を経て、株式会社バイオシス・テクノロジーズを設立（現代表取締役）。 蛋白質の分離分析技術に精通しており、国内外の研究者、企業と幅広いネットワークを持つ。現在、臨床プロテオミクスを用いたバイオマーカー、創薬探索スクリーニング技術の開発を行っている。

Business Development (Chemical Analysis Technology, Analytical Instrumentation)
　Completed Master of Science Administration, St. Michael's College, Vermont (M.S.). After founding Cypress International, Inc. (former President) and establishing the Analytical Division of AMR Corporation (current Director), I established Biosys Technologies, Inc. (current President). I am well versed in protein separation and analysis technologies, and have an extensive network of domestic and international researchers and companies. Currently, I am developing biomarker and drug discovery screening technologies using clinical proteomics.

取締役

田中 喜之 (Nobuyuki Tanaka, Managing Director)

経営（管理、財務）／事業開発（AI、IT）
　東京大学大学院（科学基礎論大講座）修士課程修了の後、2002年ソフトウェア開発ドリームテクノロジーズの取締役に就任、以後9年間取締役を務める。戦略企画室室長を経てホールディングカンパニーとなった同社の運営に関わり、企業再編やM＆Aを法務担当者として実現し、事業責任者として米国セキュリティソフトウェア日本法人の代表をはじめ、IT、通信、製造小売等、多業種のマネジメントを経験した。 2011年より国内外の新規事業開発を経て、2014年株式会社アーリーリフレクション代表取締役に就任。

Management (administration, finance) / Business Development (AI, IT)
　After completing a master's degree at the University of Tokyo Graduate School of Science, I became a director of Dream Technologies, a software development company, in 2002 and served as a director for the next nine years. After serving as the head of the Strategic Planning Office, I was involved in the management of the company, which became a holding company, and realized corporate restructuring and M&A as a legal representative. As the head of business, he was the representative of the Japanese subsidiary of US Security Software and experienced management in multiple industries, including IT, telecommunications, manufacturing and retail. After developing new businesses in Japan and abroad since 2011, I became Representative Director of Early Reflection, Inc. in 2014.

アドバイザー

Jacques Corbeil, PhD (Advisor)

Canada Research Chair in Medical Genomics, Full Professor, Department of Molecular Medicine, Faculty of Medicine, Université Laval Dr. Jacques Corbeil focuses on using the latest techniques in bioinformatics and machine learning to support and facilitate the processes of diagnosis and prognosis, and to optimize response to treatment. Dr. Corbeil uses state-of-the-art instrumentation and big data analytics to facilitate the interpretation of complex phenotypic data. He uses next-gen sequencing and mass spectrometry, and in particular metabolomics, to study how infectious microorganisms interact with their hosts, to investigate the effects of antibiotics on our microbial flora, to explore how to design small molecules and drugs to interfere with specific microbial functions, and finally to integrate omic data into biomedical research. Dr. Corbeil works at the interface of computational and omic sciences. He received his Ph.D. from the University of New South Wales, Sydney, Australia, and completed postdoctoral training at the University of California, San Diego, where he remained as a faculty member, rising to the rank of Associate Professor until his return to Canada as the holder of the Tier 1 Canada Research Chair in Medical Genomics (2004-present). Dr. Corbeil has extensive business experience having worked with Salmedix, Autogenomics, Silicon Kinetics, Peaxy and being a founder of Genocean and founding partner at Linearis ventures.

技術顧問

津田 正史 Ph.D. (Technical Advisor)

高知大学 教育研究部 総合科学系 複合領域科学部門 教授
1995年北海道大学にて博士号取得（薬学）。1998年同大学大学院薬学研究科助手、2001年同助教授を経て、2007年高知大学海洋コア総合研究センター教授に就任し、現在に至る。 専門は海洋天然物化学、分析化学。主な研究テーマは、海洋渦鞭毛藻由来の抗がん剤リード分子や細胞増殖促進物質の探索研究や、動的核偏極(DNP)を用いた異核種核磁気共鳴イメージング研究などの実績があり、複数の特許を有する。

Professor, Division of Multidisciplinary Sciences, Department of Education and Research, Kochi University
After obtaining Ph.D. in Pharmaceutical Sciences from Hokkaido University in 1995, he became an assistant professor at the Graduate School of Pharmaceutical Sciences in 1998, an assistant professor in 2001, and a professor at the Marine Core Research Center, Kochi University, in 2007. I specialize in marine natural product chemistry and analytical chemistry. My main research interests include exploratory studies of marine dinoflagellate-derived anti-cancer lead molecules and cell growth stimulants, and heteronuclear nuclear magnetic resonance imaging studies using dynamic nuclear polarization (DNP), for which I hold several patents.